公开(公告)号：US09918635B2

公开(公告)日：2018-03-20

申请号：US12818310

申请日：2010-06-18

申请人： Steven Bousamra ,  Stefan Weinert ,  Juergen Rasch-Menges ,  P. Douglas Walling ,  John F. Price ,  Heino Eikmeier ,  Birgit Kraeling ,  Karl Werner ,  Ulrich Porsch

发明人： Steven Bousamra ,  Stefan Weinert ,  Juergen Rasch-Menges ,  P. Douglas Walling ,  John F. Price ,  Heino Eikmeier ,  Birgit Kraeling ,  Karl Werner ,  Ulrich Porsch

IPC分类号： A61B5/00 ,  A61B5/145 ,  G06F19/00 ,  A61M31/00 ,  A61B5/05 ,  C12Q1/00

CPC分类号： A61B5/0002 ,  A61B5/05 ,  A61B5/14532 ,  A61B5/14546 ,  A61M31/00 ,  A61M2230/201 ,  C12Q1/006 ,  G06F19/00 ,  G06F19/3418 ,  G06F19/3456 ,  G16H10/20 ,  G16H10/40 ,  G16H20/17 ,  G16H80/00

摘要： Embodiments of a testing method suitable for diabetic persons to optimize their administered insulin dosage comprise collecting one or more sampling sets of biomarker data, wherein each sampling set comprises a sufficient plurality of non-adverse sampling instances and wherein each sampling instance comprises an acceptable biomarker reading at a single point in time recorded upon compliance with adherence criteria, determining a biomarker sampling parameter from each sampling set, comparing the biomarker sampling parameter to a target biomarker range, calculating an insulin adjustment parameter associated with the biomarker sampling parameter if the biomarker sampling parameter falls outside the target biomarker range, adjusting the insulin dosage by the insulin adjustment parameter if the biomarker sampling parameter falls outside the target biomarker range and if the insulin dosage does not exceed maximum dosage, and exiting the testing method if the adjusted insulin dosage is optimized. The insulin dosage is optimized when one or more biomarker sampling parameters fall within a target biomarker range.

公开(公告)号：US20110015511A1

公开(公告)日：2011-01-20

申请号：US12818310

申请日：2010-06-18

申请人： Steven Bousamra ,  Stefan Weinert ,  Juergen Rasch-Menges ,  P. Douglas Walling ,  John F. Price ,  Heino Eikmeier ,  Birgit Kraeling ,  Karl Werner ,  Ulrich Porsch

发明人： Steven Bousamra ,  Stefan Weinert ,  Juergen Rasch-Menges ,  P. Douglas Walling ,  John F. Price ,  Heino Eikmeier ,  Birgit Kraeling ,  Karl Werner ,  Ulrich Porsch

IPC分类号： A61B5/145 ,  G06F19/00 ,  G01N33/48 ,  G09B23/28

CPC分类号： A61B5/0002 ,  A61B5/05 ,  A61B5/14532 ,  A61B5/14546 ,  A61M31/00 ,  A61M2230/201 ,  C12Q1/006 ,  G06F19/00 ,  G06F19/3418 ,  G06F19/3456 ,  G16H10/20 ,  G16H10/40 ,  G16H20/17 ,  G16H80/00

摘要： Embodiments of a testing method suitable for diabetic persons to optimize their administered insulin dosage comprise collecting one or more sampling sets of biomarker data, wherein each sampling set comprises a sufficient plurality of non-adverse sampling instances and wherein each sampling instance comprises an acceptable biomarker reading at a single point in time recorded upon compliance with adherence criteria, determining a biomarker sampling parameter from each sampling set, comparing the biomarker sampling parameter to a target biomarker range, calculating an insulin adjustment parameter associated with the biomarker sampling parameter if the biomarker sampling parameter falls outside the target biomarker range, adjusting the insulin dosage by the insulin adjustment parameter if the biomarker sampling parameter falls outside the target biomarker range and if the insulin dosage does not exceed maximum dosage, and exiting the testing method if the adjusted insulin dosage is optimized. The insulin dosage is optimized when one or more biomarker sampling parameters fall within a target biomarker range.

摘要翻译： 适于糖尿病患者优化其施用的胰岛素剂量的测试方法的实施方案包括收集一个或多个生物标志物数据的采样组，其中每个采样组包括足够多个非不良采样实例，并且其中每个采样实例包括可接受的生物标志物读数 在符合遵守标准的单个时间点上，从每个采样组确定生物标志物采样参数，将生物标志物采样参数与目标生物标志物范围进行比较，计算与生物标志物采样参数相关联的胰岛素调节参数，如果生物标志物采样参数 如果生物标志物采样参数落在目标生物标志物范围之外，并且如果胰岛素剂量不超过最大剂量，并且如果调整的胰岛素剂量是最佳的则退出测试方法，则超出目标生物标志物范围，通过胰岛素调节参数调整胰岛素剂量 zed。 当一个或多个生物标志物采样参数落入目标生物标志物范围内时，胰岛素剂量被优化。